|Table of Contents|

The predictive value of NLR,PLR and SII in the prognosis of patients with immunotherapy for non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
461-465
Research Field:
Publishing date:

Info

Title:
The predictive value of NLR,PLR and SII in the prognosis of patients with immunotherapy for non-small cell lung cancer
Author(s):
GU Ling1; 2; HENG Wei2
1.Changshu First People's Hospital,Jiangsu Changshu 215500,China;2.First Affiliated Hospital of Soochow University,Jiangsu Suzhou 215006,China.
Keywords:
NSCLC; NLR; SII; immunotherapy; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.03.012
Abstract:
Objective:To explore the predictive role of peripheral blood inflammatory markers in patients with stage Ⅳ non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors(ICIs).Methods:A retrospective analysis was conducted on the clinical data of 122 patients with stage Ⅳ NSCLC who received two or more cycles of immunotherapy in the Department of Respiratory and Critical Care Medicine at the First Affiliated Hospital of Soochow University from January 1,2019 to September 30,2021.They were grouped according to the level of NLR,PLR,and SII and analyzed using IBM SPSS Statistics 23.0 software.Results:Cox multivariate analysis showed that the combination of ICI,chemotherapy and anti-angiogenesis therapy is an independent protective factor affecting PFS,while baseline use of glucocorticoids is an independent risk factor affecting PFS.The presence or absence of liver metastasis and baseline NLR are independent factors affecting the survival time of patients with advanced NSCLC.Patients with liver metastasis and baseline NLR≥3.3 have a significantly increased risk of death.Conclusion:The level of peripheral blood inflammation is closely related to the prognosis of immunotherapy in advanced NSCLC patients.Baseline low NLR patients have better lesion relief and longer survival,and patients with sustained low NLR benefit more significantly.

References:

［1］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73(1):17-48.
［2］ROSELL R,KARACHALIOU N.Large-scale screening for somatic mutations in lung cancer［J］.LANCET,2016,387(10026):1354-1356.
［3］RECK M,RODRIGUEZ-ABREU D,ROBINSON A G,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer［J］.The New England Journal of Medicine,2016,375(19):1823-1833.
［4］RODRIGUEZ-ABREU D,POWELL SF,HOCHMAIR MJ,et al.Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC:protocol-specified final analysis from KEYNOTE-189［J］.Annals of Oncology,2021,32(7):881-895.
［5］BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,373(2):123-135.
［6］XIA L,LIU Y,WANG Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer:Current status and future directions［J］.The Oncologist,2019,24(Suppl 1):S31-S41.
［7］RAKAEE M,ADIB E,RICCIUTI B,et al.Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC［J］.JAMA Oncology,2023,9(1):51-60.
［8］VALERO C,LEE M,HOEN D,et al.Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors［J］.Nature Communications,2021,12(1):729.
［9］HWANG M,CANZONIERO JV,ROSNER S,et al.Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy［J］.Journal for Immunotherapy of Cancer,2022,10(6):1136-1148.
［10］REBUZZI SE,SIGNORI A,STELLATO M,et al.The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab:The Delta-Meet-URO analysis［J］.Frontiers in Oncology,2022,12:501-515.
［11］VINAL D,GUTIERREZ-SAINZ L,MARTINEZ D,et al.Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy［J］.Clinical & Translational Oncology,2021,23(6):1185-1192.
［12］GOU M,QU T,WANG Z,et al.Neutrophil-to-lymphocyte ratio(NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric cancer［J］.Journal of Immunology Research,2021,2021:254-295.
［13］JOMRICH G,GRUBER ES,WINKLER D,et al.Systemic immune-inflammation index(SII) predicts poor survival in pancreatic cancer patients undergoing resection［J］.Journal of Gastrointestinal Surgery,2020,24(3):610-618.
［14］LIU P,CHEN S,GAO X,et al.Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer［J］.Frontiers in Immunology,2022,13:329-340.
［15］PAVAN A,CALVETTI L,DAL MASO A,et al.Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors［J］.The Oncologist,2019,24(8):1128-1136.
［16］LIU J,LI S,ZHANG S,et al.Systemic immune-inflammation index,neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab［J］.Journal of Clinical Laboratory Analysis,2019,33(8):296.
［17］REN F,ZHAO T,LIU B,et al.Neutrophil-lymphocyte ratio(NLR) predicted prognosis for advanced non-small-cell lung cancer(NSCLC) patients who received immune checkpoint blockade(ICB)［J］.OncoTargets and Therapy,2019,12:4235-4244.
［18］SCHOENFELD AJ,RIZVI H,BANDLAMUDI C,et al.Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas［J］.Annals of Oncology,2020,31(5):599-608.
［19］SUI H,MA N,WANG Y,et al.Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer:Toward personalized medicine and combination strategies［J］.Journal of Immunology Research,2018,2018(6):948-984.
［20］MULLER I,MUNDER M,KROPF P,et al.Polymorphonuclear neutrophils and T lymphocytes:Strange bedfellows or brothers in arms［J］.Trends in Immunology,2009,30(11):522-530.
［21］FERRONE C,DRANOFF G.Dual roles for immunity in gastrointestinal cancers［J］.Journal of Clinical Oncology,2010,28(26):4045-4051.
［22］PENG L,WANG Y,LIU F,et al.Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors［J］.Cancer Immunology,Immunotherapy,2020,69(9):1813-1822.
［23］LIM JU,KANG HS,YEO CD,et al.Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors［J］.Journal of Thoracic Disease,2021,13(5):2824-2832.
［24］PLATINI H,FERDINAND E,KOHAR K,et al.Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers for advanced non-small-cell lung cancer treated with immunotherapy:A systematic review and Meta-analysis［J］.Medicina(Kaunas,Lithuania),2022,58(8):1069-1085.
［25］HU B,YANG XR,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］.Clinical Cancer Research,2014,20(23):6212-6222.
［26］ZHENG L,ZOU K,YANG C,et al.Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients［J］.Clinical & Translational Oncology,2017,19(9):1125-1132.
［27］LI C,WU J,JIANG L,et al.The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment:A multi-center study［J］.Cancer Immunology Immunotherapy,2023,72(3):783-794.
［28］ARBOUR KC,MEZQUITA L,LONG N,et al.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death ligand 1 blockade in patients with non-small cell lung cancer［J］.Journal of Clinical Oncology,2018,36(28):2872-2878.
［29］DE GIGLIO A,APRILE M,DI FEDERICO A,et al.Impact of baseline versus intercurrent steroids administration on upfront chemo-immunotherapy for advanced non-small cell lung cancer(NSCLC)［J］.International Journal of Molecular Sciences,2022,23(18):292-299.
［30］DAFNI U,TSOURTI Z,VERVITA K,et al.Immune checkpoint inhibitors,alone or in combination with chemotherapy,as first-line treatment for advanced non-small cell lung cancer.A systematic review and network meta-analysis［J］.Lung Cancer,2019,134:127-140.
［31］SUN D,LIU J,ZHOU H,et al.Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC［J］.Journal of Thoracic Oncology,2023,18(7):869-881.
［32］QIAO M,ZHOU F,HOU L,et al.Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases［J］.Annals of Translational Medicine,2021,9(1):34.
［33］YU J,GREEN MD,LI S,et al.Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination［J］.Nature Medicine,2021,27(1):152-164.

Memo

Memo:
-
Last Update: 2023-12-29